Business

PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity

PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor R...

articlePharmacielo Ltd.December 18, 20205/company/pharmacielo-ltd/news/pharmacielo-announces-appointment-of-caroline-lenardon-for-expansion-of-retail-investor-relations-capacity
PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity

About this update from Pharmacielo Ltd.

[{"type":"text","content":"\n \n \n \n PharmaCielo Announces Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n TORONTO\n \n ,\n \n Dec. 18, 2020\n \n /CNW/ - PharmaCielo Ltd. (\"PharmaCielo\" or the \"Company\") (TSXV: PCLO), the Canadian parent of\n \n Colombia's\n \n premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S. today announced that the company has expanded investor relations support capacity with the appointment of\n \n Caroline Lenardon\n \n to provide investor relations services to the Company\n \n \n with a focus on retail investment.\n \n \n The institutional investor market will continue to be supported by the existing contractor.\n \n \n \n \n \n \n \n \n \n In consideration of the services to be provided by Ms. Lenardon, monthly fees will be incurred and the board of directors of the Company approved the grant to Ms. Lenardon of 100,000 stock options (\"\n \n Stock Options\n \n \") exercisable for common shares of the Company at a price of\n \n $2.18\n \n for a period of three years from the grant date. The Stock Options vest one fourth immediately, one fourth at four months, one fourth at eight months and one fourth at twelve months, from the grant date, respectively.\n \n \n \n About PharmaCielo\n \n \n \n PharmaCielo Ltd. (TSXV: PCLO, OTCQX: PCLOF) is a global company, headquartered in\n \n Canada\n \n , with a focus on ethical and sustainable processing and supplying of all natural, medicinal-grade cannabis oil extracts and related products to large channel distributors. PharmaCielo's principal (and wholly owned) subsidiary is PharmaCielo Colombia Holdings S.A.S., based at its cultivation and processing complex located in Rionegro,\n \n Colombia\n \n .\n \n \n The board of directors and executive team of PharmaCielo are comprised of a diversely talented group of international business executives and specialists with relevant and varied expertise. PharmaCielo recognized the significant role that\n \...

More updates from Pharmacielo Ltd.